Effect of infliximab on tumor necrosis factor-alpha-induced alterations in retinal microvascular endothelial cells and retinal pigment epithelial cells

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 6, 2010, Pages 549-556

  Li, Huili ^a   Yoneda, Masahiko ^b   Takeyama, Masayuki ^a   Sugita, Iichiro ^a   Tsunekawa, Hinako ^a   Yamada, Hiroshi ^a   Watanabe, Daisuke ^a   Mukai, Tomoyuki ^a   Yamamura, Masahiro ^a   Iwaki, Masayoshi ^a   Zako, Masahiro ^a  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b Aichi Prefectural College of Nursing and Health   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DODECYL SULFATE SODIUM; GELATINASE A; GELATINASE B; INFLIXIMAB; INTERSTITIAL COLLAGENASE; MESSENGER RNA; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PIGMENT EPITHELIUM; POLYACRYLAMIDE GEL ELECTROPHORESIS; REAL TIME POLYMERASE CHAIN REACTION; RETINA BLOOD VESSEL;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BLOOD-RETINAL BARRIER; CELL LINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HUMANS; MATRIX METALLOPROTEINASES; POLYMERASE CHAIN REACTION; RETINAL PIGMENT EPITHELIUM; RETINAL VESSELS; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649712468     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0079     Document Type: Article

References (51)

1. Mege, J.L., Dilsen, N., Sanguedolce, V., Gul, A., Bongrand, P., Roux, H., Ocal, L., Inanç, M., and Capo, C. Overproduction of monocyte-derive TNF-α, IL-β, IL-γ and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J. Rheumatol. 20:1544-1549, 1993.
2. Direskeneli, H. Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann. Rheum. Dis. 60:996-1002, 2001.
3. Turan, B., Gallati, H., Erdi, H., Gurler, A., Michel, B.A., and Villiger, P.M. Systemic levels of the T cell regulatory cyto-kines IL-10 and IL-12 in Behçet's disease; soluble TNFR-75 as a biological marker of disease activity. J. Rheumatol. 24:128-132, 1997.
4. Santos Lacomba, M., Marcos Mart́n, C., Gallardo Galera, J.M., Gómez Vidal, M.A., Collantes Estévez, E., Raḿrez Chamond, R., and Omar, M. Aqueous humor and serum tumor necrosis factor-a in clinical uveitis. Ophthalmic. Res. 33:251-255, 2001.
5. Arayssi, T.A., and Hamdan, A. New insights into the path-ogenesis and therapy of Behçet's disease. Curr. Opin. Pharmacol. 4:183-188, 2004.
6. Ozdamar, Y., Berker, N., Bahar, G., Soykan, E., Bicer, T., Ozkan, S.S., and Karakaya, J. Inflammatory mediators and posterior segment involvement in ocular Behcet disease. Eur. J. Ophthalmol. 19:998-1003, 2009.
7. Sfikakis, P.P., Theodossiadis, P.G., Katsiari, C.G., Kaklama-nis, P., and Markomichelakis, N.N. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 358: 295-296, 2001.
8. Joseph, A., Raj, D., Dua, H.S., Powell, P.T., Lanyon, P.C., and Powell, R.J. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 110:1449-1453, 2003.
9. Ohno, S., Nakamura, S., Hori, S., Shimakawa, M., Kawa-shima, H., Mochizuki, M., Sugita, S., Ueno, S., Yoshizaki, K., and Inaba, G. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J. Rheumatol. 31:1362-1368, 2004.
10. Baughman, R.P., Bradley, D.A., and Lower, E.E. Infliximab in chronic ocular inflammation. Int. J. Clin. Pharmacol. Ther. 43:7-11, 2005.
11. Tugal-Tutkun, I., Mudun, A., Urgancioglu, M., Kamali, S., Kasapoglu, E., Inanc, M., and Gül, A. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and cortico-steroids in Behçet's disease: an open-label trial. Arthritis Rheum. 52:2478-2484, 2005.
12. Lindstedt, E.W., Baarsma, G.S., Kuijpers, R.W., and van Hagen, P.M. Anti-TNF-alpha therapy for sight threatening uveitis. Br. J. Ophthalmol. 89:533-536, 2005.
13. Elezoglou, A., Kafasi, N., Kaklamanis, P.H., Theodossiadis, P.G., Kapsimali, V., Choremi, E., Vaiopoulos, G., and Sfika-kis, P.P. Infliximab treatment-induced formation of auto-antibodies is common in Behçet's disease. Clin. Exp. Rheumatol. 25:S65-S69, 2007.
14. Kikuchi, H., Aramaki, K., and Hirohata, S. Effect of in-fliximab in progressive neuro-Behçet's syndrome. J. Neurol. Sci. 272:99-105, 2008.
15. Calamia, K.T., and Kaklamanis, P.G. Behçet's disease: recent advances in early diagnosis and effective treatment. Curr. Rheumatol. Rep. 10:349-355, 2008.
16. Al-Rayes, H., Al-Swailem, R., Al-Balawi, M., Al-Dohayan, N., Al-Zaidi, S., and Tariq, M. Safety and efficacy of in-fliximab therapy in active Behcet's uveitis: an open-label trial. Rheumatol. Int. 29:53-57, 2008.
17. Petropoulos, I.K., Vaudaux, J.D., and Guex-Crosier, Y. Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital. Klin. Monatsbl. Augenheilkd. 225:457-461, 2008.
18. Tabbara, K.F., and Al-Hemidan, A.I. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am. J. Ophthalmol. 146: 845-850, 2008.
19. Wang, Y., and Gaudio, P.A. Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome. Ocul. Immunol. In-flamm. 16:167-171, 2008.
20. Lopez-Gonzalez, R., Loza, E., Jover, J.A., Benitez Del Castillo, J.M., Mendez, R., Hernandez-Garcia, C., and Pato, E. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study. Scand. J. Rheumatol. 38:58-62, 2009.
21. Niccoli, L., Nannini, C., Cassarà, E., Gini, G., Lenzetti, I., and Cantini, F. Efficacy of infliximab therapy in two patients with refractory Vogt-Koyanagi-Harada disease. Br. J. Oph-thalmol. 93:1553-1554, 2009.
22. Nelson, A.R., Fingleton, B., Rothenberg, M.L., and Matrisian, L.M. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. 18:1135-1149, 2000.
23. Sternlicht, M.D., and Bergers, G. Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects. Emerg. Ther. Targets 4:609-633, 2000.
24. Sternlicht, M.D., and Werb, Z. How matrix metalloprotei-nases regulate cell behavior. Annu. Rev. Cell. Dev. Biol. 17:463-516, 2001.
25. Zhang, X., Sakamoto, T., Hata, Y., Kubota, T., Hisatomi, T., Murata, T., Ishibashi, T., and Inomata, H. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats. Exp. Eye Res. 74: 577-584, 2002.
26. Pay, S., Erdem, H., Serdar, M., Dinç, A., Sim̧sek, I., and Turan, M. Comparison of synovial MMP-1 and TIMP-1 levels in patients with various inflammatory arthritides: is there any difference between rheumatoid arthritis, Behçet's disease and familial Mediterranean fever? Clin. Rheumatol. 21:511-515, 2002.
27. Eichler, W., Friedrichs, U., Thies, A., Tratz, C., and Wiede-mann, P. Modulation of matrix metalloproteinase and TIMP-1 expression by cytokines in human RPE cells. Invest. Oph-thalmol. Vis. Sci. 43:2767-2773, 2002.
28. Felkin, L.E., Birks, E.J., George, R., Wong, S., Khaghani, A., Yacoub, M.H., and Barton, P.J. A quantitative gene expression profile of matrix metalloproteinases (MMPS) and their inhibitors (TIMPS) in the myocardium of patients with deteriorating heart failure requiring left ventricular assist device support. J. Heart Lung Transplant. 25:1413-1419, 2006.
29. Morán, A., Iniesta, P., de Juan, C., González-Quevedo, R., Sánchez-Pernaute, A., D?́az-Rubio, E., Ramóny Cajal, S., Torres, A., Balibrea, J.L., and Benito, M. Stromelysin-1 promoter mutations impair gelatinase B activation in high mi-crosatellite instability sporadic colorectal tumors. Cancer Res. 62:3855-3860, 2002.
30. Kosar, A., Haznedaroglu, S., Karaaslan, Y., Bü yü kasik, Y., Haznedaroglu, I.C., Ozath, D., Sayinalp, N., Ozcebe, O., Kirazli, S., and Dü ndar, S. Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, inter-leukin-2 receptor, and E-selectin in Behçet's disease. Rheu-matol. Int. 19:11-14, 1999.
31. Evereklioglu, C., Er, H., Türköz, Y., and Cekmen, M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm. 11:87-93, 2002.
32. Oztas, M.O., Onder, M., Gurer, M.A., Bukan, N., and Sancak, B. Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet's disease. Clin. Exp. Dermatol. 30:61-63, 2005.
33. Ahn, J.K., Yu, H.G., Chung, H., and Park, Y.G. Intraocular cytokine environment in active Behçet uveitis. Am. J. Oph-thalmol. 142:429-434, 2006.
34. Klimiuk, P.A., Sierakowski, S., Domyslawska, I., and Chwiecko, J. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metallo-proteinases in patients with rheumatoid arthritis. J. Rheu-matol. 31:238-242, 2004.
35. Maksymowych, W.P., Jhangri, G.S., Lambert, R.G., Mallon, C., Buenviaje, H., Pedrycz, E., Luongo, R., and Russell, A.S. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J. Rheumatol. 29:959-965, 2002.
36. Durez, P., Nzeusseu Toukap, A., Lauwerys, B.R., Manicourt, D.H., Verschueren, P., Westhovens, R., Devogelaer, J.P., and Houssiau, F.A. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Ann. Rheum. Dis. 63:1069-1074, 2004.
37. Vandooren, B., Kruithof, E., Yu, D.T., Rihl, M., Gu, J., De Rycke, L., Van Den Bosch, F., Veys, E.M., De Keyser, F., and Baeten, D. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondyloarthropathy. Arthritis Rheum. 50:2942-2953, 2004.
38. Yang, C, Gu, J., Rihl, M., Baeten, D., Huang, F., Zhao, M., Zhang, H., Maksymowych, W.P., De Keyser, F., Veys, E.M., and Yu, D.T. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum. 51:691-699, 2004.
39. Visvanathan, S., Marini, J.C., Smolen, J.S., Clair, E.W., Pritchard, C., Shergy, W., Pendley, C., Baker, D., Bala, M., Gathany, T., Han, J., and Wagner, C. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. J. Rheumatol. 34:1465-1474, 2007.
40. Gao, Q., Meijer, M.J., Schlüter, U.G., van Hogezand, R.A., van der Zon, J.M., van den Berg, M., van Duijn, W., Lamers, C.B., and Verspaget, H.W. Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and\9 in Crohn's disease. Inflamm. Bowel Dis. 13:693-702, 2007.
41. Cordiali-Fei, P., Trento, E., D'Agosto, G., Bordignon, V., Mussi, A., Ardigo, M., Mastroianni, A., Vento, A., Solivetti, F., Berardesca, E., and Ensoli, F. Decreased levels of me-talloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-alpha. J. Autoimmune Dis. 3:5, 2006.
42. Lindberg, J., Klint, E., Catrina, A.I., Nilsson, P., Klareskog, L., Ulfgren, A.K., and Lundeberg, J. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res. Ther. 8:R179, 2006.
43. Kruithof, E., De Rycke, L., Vandooren, B., De Keyser, F., FitzGerald, O., McInnes, I., Tak, P.P., Bresnihan, B., Veys, E.M., and Baeten, D. Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum. 54:1795-1804, 2006.
44. Meijer, M.J., Mieremet-Ooms, M.A., van Duijn, W., van der Zon, A.M., Hanemaaijer, R., Verheijen, J.H., van Hogezand, R.A., Lamers, C.B., and Verspaget, H.W. Effect of the antitumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm. Bowel Dis. 13:200-210, 2007.
45. Hoffmann, S., He, S., Ehren, M., Ryan, S.J., Wiedemann, P., and Hinton, D.R. MMP-2 and MMP-9 secretion by rpe is stimulated by angiogenic molecules found in choroidal neovascular membranes. Retina 26:454-461, 2006.
46. Mannermaa, E., Reinisalo, M., Ranta, V.P., Vellonen, K.S., Kokki, H., Saarikko, A., Kaarniranta, K., and Urtti, A. Filter cultured ARPE-19 cells as outer blood-retinal barrier model. Eur. J. Pharm. Sci. 40:289-296, 2010.
47. El-Shabrawi, Y.G., Christen, W.G., and Foster, S.C. Correlation of metalloproteinase-2 and\9 with proinflammatory cytokines interleukin-1b, interleukin-12 and the interleukin-1 receptor antagonist in patients with chronic uveitis. Curr. Eye Res. 20:211-214, 2000.
48. Di Girolamo, N., Verma, M.J., McCluskey, P.J., Lloyd, A., and Wakefield, D. Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis. Curr. Eye Res. 15:1060-1068, 1996.
49. Davis, G.E., and Senger, D.R. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 97:1093-1107, 2005.
50. Davis, G.E., and Senger, D.R. Extracellular matrix mediates a molecular balance between vascular morphogenesis and regression. Curr. Opin. Hematol. 15:197-203, 2008.
51. Pardo, A., and Selman, M. MMP-1: the elder of the family. Int. J. Biochem. Cell Biol. 37:283-288, 2005.